Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies

Haijun Chen, Yu Gao, Jianlei Wu, Yingyu Chen, Buyuan Chen, Jianda Hu, Jia Zhou

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized.

Original languageEnglish (US)
Pages (from-to)5-11
Number of pages7
JournalCancer Letters
Volume354
Issue number1
DOIs
StatePublished - Nov 1 2014

Fingerprint

Hematologic Neoplasms
Chemoprevention
Flavonoids
Drug Discovery
Therapeutics
Biotransformation
Biological Products
Biological Availability
Pharmacology
baicalin
baicalein
Research

Keywords

  • Baicalein
  • Baicalin
  • Cancer targets
  • Flavonoids
  • Hematological malignancies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. / Chen, Haijun; Gao, Yu; Wu, Jianlei; Chen, Yingyu; Chen, Buyuan; Hu, Jianda; Zhou, Jia.

In: Cancer Letters, Vol. 354, No. 1, 01.11.2014, p. 5-11.

Research output: Contribution to journalArticle

Chen, Haijun ; Gao, Yu ; Wu, Jianlei ; Chen, Yingyu ; Chen, Buyuan ; Hu, Jianda ; Zhou, Jia. / Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies. In: Cancer Letters. 2014 ; Vol. 354, No. 1. pp. 5-11.
@article{eba7e9bb96ba4a8db50b3af941bacf5d,
title = "Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies",
abstract = "Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized.",
keywords = "Baicalein, Baicalin, Cancer targets, Flavonoids, Hematological malignancies",
author = "Haijun Chen and Yu Gao and Jianlei Wu and Yingyu Chen and Buyuan Chen and Jianda Hu and Jia Zhou",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.canlet.2014.08.003",
language = "English (US)",
volume = "354",
pages = "5--11",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Exploring therapeutic potentials of baicalin and its aglycone baicalein for hematological malignancies

AU - Chen, Haijun

AU - Gao, Yu

AU - Wu, Jianlei

AU - Chen, Yingyu

AU - Chen, Buyuan

AU - Hu, Jianda

AU - Zhou, Jia

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized.

AB - Despite tremendous advances in the targeted therapy for various types of hematological malignancies with successful improvements in the survival rates, emerging resistance issues are startlingly high and novel therapeutic strategies are urgently needed. In addition, chemoprevention is currently becoming an elusive goal. Plant-derived natural products have garnered considerable attention in recent years due to the potential dual functions as chemotherapeutics and dietary chemoprevention. One of the particularly ubiquitous families is the polyphenolic flavonoids. Among them, baicalin and its aglycone baicalein have been widely investigated in hematological malignancies because both of them exhibit remarkable pharmacological properties. This review focuses on the recent achievements in drug discovery research associated with baicalin and baicalein for hematological malignancy therapies. The promising anticancer activities of these two flavonoids targeting diverse signaling pathways and their potential biological mechanisms in different types of hematological malignancies, as well as the combination strategy with baicalin or baicalein as chemotherapeutic adjuvants for recent therapies in these intractable diseases are discussed. Meanwhile, the biotransformation of baicalin and baicalein and the relevant approaches to improve their bioavailability are also summarized.

KW - Baicalein

KW - Baicalin

KW - Cancer targets

KW - Flavonoids

KW - Hematological malignancies

UR - http://www.scopus.com/inward/record.url?scp=84910006077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910006077&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.08.003

DO - 10.1016/j.canlet.2014.08.003

M3 - Article

VL - 354

SP - 5

EP - 11

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -